Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany-Reference-Cited by-同舟云学术

Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany

Published:2023-06 Issue:6 Volume:26 Page:854-864
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Schiller Juliane,Eckhardt Helene,Schmitter Sarah,Alber Valerie A.,Rombey Tanja

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference91 articles.

1. An overview of precision oncology basket and umbrella trials for clinicians;Park;CA Cancer J Clin,2020

2. Tumour-agnostic therapies;Looney;Nat Rev Drug Discov,2020

3. Fachkreise-Redaktion des Krebsinformationsdienstes. What is tumor-agnostic cancer therapy? [Was ist eine tumoragnostische Krebstherapie?]. https://www.krebsinformationsdienst.de/fachkreise/nachrichten/2019/fk06-tumor-agnostisch-personalisierte-medizin-krebs.php. Accessed October 4, 2021.

4. Site-agnostic biomarker-guided oncology drug development;Jørgensen;Expert Rev Mol Diagn,2020

5. Bundesgesetzblatt 2010. German Pharmaceutical Market Reorganization Act - AMNOG [Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz - AMNOG)]. https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F∗[%40attr_id%3D%27bgbl110s2262.pdf%27]#__bgbl__%2F%2F∗%5B%40attr_id%3D%27bgbl110s2262.pdf%27%5D/1640675684226. Accessed December 28, 2021.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08

2. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned;Drug Discovery Today;2024-07

3. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with RET -altered solid tumors in the US;Journal of Medical Economics;2024-03-06

4. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions;Value in Health;2023-11